This study is comparing two ways to perform a prostate biopsy (a procedure to remove small tissue samples for examination) when prostate cancer is suspected based on an MRI scan. One method, called "Software fusion prostate biopsy," uses special software to combine MRI and ultrasound images to guide the biopsy. The other, "Cognitive fusion prostate biopsy," relies on a doctor's visual estimation and measurements from the MRI. The goal is to see which method is better at finding clinically significant prostate cancer (cancer that needs treatment). You might be able to join if you are a man aged 18 or older, need a prostate biopsy for suspected cancer, and have not had a biopsy in the last three years. The study aims to enroll 1306 participants.

Study design

This is an interventional study comparing two different biopsy techniques. It plans to enroll 1306 men.

What's involved

You would undergo either a software fusion or cognitive fusion prostate biopsy, where three tissue samples are taken per suspected lesion, up to a maximum of three lesions.

Compensation

Not stated in the trial record.

Follow-up

The study will measure the detection of clinically significant prostate cancer at 1 year after the biopsy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.